Best Practices Kicks off 2014-2015 Medical Affairs Consortium

Author:

Medical Affairs functions have a significant influence on a healthcare company’s overall success. As the pharmaceutical, biotech, medical device, and health care technology markets become increasingly competitive and complex, it is crucial for leaders to understand how to best operate and manage their companies. Since the growth of biotechnology in the past decade has been quite impressive, executives desire the knowledge of how to best drive company growth and continued innovation.

Best Practices’ 2014-2015 Medical Affairs Consortium kicked off on July 1st with the member-driven topic selection stage. This year’s research topics may include, but are not limited to:

  • Managing Globalization in Medical Affairs: Reporting structure, leadership oversight, resources, budgeting decisions, operational challenges, managing globally and delivering locally.
  • Medical Affairs’ Role in a Health Outcomes Oriented Environment: Roles and responsibilities, health outcomes data usage, stakeholders engaged, HOL group structure, resources & budget, talent acquisition & training, HOL-MSL differentiation, engaging with ACOs.
  • Medical Affairs’ Evolving Role in Product Launch: Product Launch planning, resources & budgeting, thought leader interactions, scientific publications, launch activities and timing.
  • Medical Affairs’ Impact Measures: Objectives, MA sub-function metrics, frequency of measurement, tools and technologies, effectiveness.
  • Continuing Medical Education: Resources, structure, CME delivery channels and services, emerging educator groups.
  • Scientific Communication and Publication: Strategy and planning responsibility, successful communication tactics, publication vehicle, content type, target audience.
  • Investigator Initiated Trials: IIT, IIS strategy, oversight and performance, IIT data usage.

Companies participating in this year’s Medical Affairs Consortium include, but are not limited to: Amgen, Astellas, Astra Zeneca, Baxter, Biogen Idec, Eli Lilly, Genentech, Merck, Novartis, Pfizer, ProStrakan, Sanofi, Upsher-Smith, and Teva.

Currently, consortium leaders are choosing the study topics that will best address the needs of Medical Affairs leaders. Following that, there will be 3 roundtable panels at which responses to the questions will be analyzed and discussed. The dates for the three panels will be announced in the near future.

For more information regarding the Medical Affairs Consortium studies, please review our Weekly Medical Affairs Consortium Research Release.

To learn more about Medical Affairs Consortium, click here.

One Response to Best Practices Kicks off 2014-2015 Medical Affairs Consortium

  1. stevenlashsandiego says:

    Excellent, what a blog it is! This web site presents valuable facts to us, keep it up.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>